US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Kailera Therapeutics (KLRA): Post-180-Day Review: Heavyweight Backers, Lightweight Returns

Kailera Therapeutics (KLRA): Bain Backed Obesity Biotech Garners Significant Interest

Kailera Therapeutics (KLRA):Phase III Obesity Biotech Sets Terms with Backing from Bain, QIA

Kailera Therapeutics (KLRA): Peeking at the IPO Prospectus of a Neurological Therapy Biotech

IPOs and Secondary Offerings

Equity Capital Markets

Kailera Therapeutics / Equity Capital Markets

<ul>
<li>Kailera Therapeutics priced upsized IPO at $16 and surged 62.5% on debut, opening at $26 with strong institutional demand and tight trading range.</li>
<li>Oversubscribed deal with concentrated allocations, signaling strong conviction from top-tier investors and disciplined bookbuilding by syndicate and management.</li>
<li>Lead obesity pipeline and Phase 3 ribupatide asset support long-term growth narrative in a structurally expanding global obesity therapeutics market.</li>
</ul>


Kailera Therapeutics priced upsized IPO at $16 and surged 62.5% on debut, opening at $26 with strong institutional demand and tight trading range.
Oversubscribed deal with concentrated allocations, signaling strong conviction from top-tier investors and disciplined bookbuilding by syndicate and management.
Lead obesity pipeline and Phase 3 ribupatide asset support long-term growth narrative in a structurally expanding global obesity therapeutics market.


Kailera Therapeutics (KLRA): Strong Appetite Fuels Kailera IPO Surge, Opens with Ten Point Premium